FTY 720 P是新型免疫抑制藥物芬戈莫德(FTY 720)的生物活性形式。FTY 720通過鞘氨醇激酶轉(zhuǎn)化為FTY 720 P,(S)-異構(gòu)體作為四種S1 P受體(S1 P1 3 4 5)的激動劑,IC 50分別為2.1、5.9、23和2.2 nM。R異構(gòu)體以低5-10倍的親和力結(jié)合。FTY 720 P通過細胞外信號調(diào)節(jié)激酶(ERK)信號通路促進新生大鼠少突膠質(zhì)細胞存活、調(diào)節(jié)少突膠質(zhì)細胞祖細胞分化、促進星形膠質(zhì)細胞遷移。最近發(fā)表的結(jié)果表明,F(xiàn)TY 720 P參與淋巴脈絡(luò)叢腦膜炎病毒(LCMV)克隆13引起的持續(xù)性感染的完全病毒清除。出版物由Bioz提供技術(shù)支持查看Bioz 1的更多詳情。布基河 等(2010年)。“血漿凝溶膠蛋白調(diào)節(jié)細胞對1-磷酸鞘氨醇的反應(yīng)。“美國生理學(xué)雜志細胞生理學(xué)299(6):C1516-1523.2。古Y。 等(2011年)。“上皮細胞擠出需要鞘氨醇-1-磷酸受體2途徑。《細胞生物學(xué)雜志》193(4):667-676.3。特爾科夫灣 等(2012年)。芬戈莫德-一種鞘氨醇樣分子抑制星形膠質(zhì)細胞中囊泡的流動性和分泌。“Glia 60(9):1406.4。薩穆韋爾灣等(2015). AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.“PLoS ONE 10(10):e0141781.5.巴以法蓮E. 等(2019)。CD 62 L是循環(huán)先天類淋巴細胞前體的功能和表型標志物。《免疫學(xué)雜志》202(1):171-182。
產(chǎn)品描述
FTY720P is the bioactive form of the novel immunosuppressive drug fingolimod (FTY720). FTY720 is converted to FTY720P by sphingosine kinase and the (S)-isomer acts as an agonist to four S1P receptors (S1P1 3 4 5) with IC50s of 2.1 5.9 23 and 2.2 nM respectively. The R isomer binds with 5-10 fold lower affinity. FTY720P improves the survival of neonatal rat oligodendrocytes regulates oligodendrocyte progenitor cells differentiation promotes astrocyte migration via extracellular signal-regulated kinase (ERK) signaling. Recently published results indicate involvement of FTY720P in complete viral clearance of persistent infection caused by clone 13 of lymphotic choriomeningitis virus (LCMV).Publications Powered by Bioz See more details on Bioz1. Bucki R. et al. (2010). "Plasma gelsolin modulates cellular response to sphingosine 1-phosphate." Am J Physiol Cell Physiol 299(6): C1516-1523.2. Gu Y. et al. (2011). "Epithelial cell extrusion requires the sphingosine-1-phosphate receptor 2 pathway." The Journal of Cell Biology 193(4): 667-676.3. Trkov S. et al. (2012). "Fingolimoda€”A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes." Glia 60(9): 1406.4. Samuvel D. J. et al. (2015). "AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis." PLoS ONE 10(10): e0141781.5. Bar-Ephraim Y. E. et al. (2019). "CD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors." The Journal of Immunology 202(1): 171-182.